Kombucha‑Related Fungal Infection (Rare)

Overview

Kombucha is a fermented tea that contains a symbiotic culture of bacteria and yeast (SCOBY). While most people consume kombucha without any problems, there are isolated reports of fungal infections linked to contaminated home‑brewed kombucha. These infections are extremely rare—most case reports involve a handful of patients worldwide over the past decade. The condition is typically referred to in the medical literature as a “SCOBY‑associated cutaneous or systemic fungal infection” and is caused by opportunistic yeasts (often Candida spp. or Saccharomyces cerevisiae) that proliferate when the brew is mishandled.

Because the infection is uncommon, exact prevalence numbers are unavailable. The CDC’s National Healthcare Safety Network recorded < 5 > confirmed kombucha‑related fungal infections in the United States between 2015‑2024, representing <0.001 % of all fungal infections reported.

The infection can affect anyone who ingests or has prolonged skin contact with a contaminated batch, but the highest‑risk groups are:

• Individuals who make kombucha at home using non‑sterile equipment.
• People with compromised immune systems (e.g., HIV/AIDS, organ‑transplant recipients, chemotherapy patients).
• Those with chronic skin breaks or dermatitis who handle the SCOBY.

Symptoms

Symptoms vary by the site of infection (skin, gastrointestinal tract, or disseminated). Below is a complete list, grouped by system:

Cutaneous (skin) infection

• Red, tender rash at the site of contact—often looks like cellulitis.
• Itching or burning sensation.
• Pustules or vesicles that may ooze a whitish discharge.
• Swelling extending beyond the initial contact area.
• Fever (low‑grade) may accompany extensive skin involvement.

Gastrointestinal infection (after ingestion)

• Nausea and vomiting within 24‑48 hours of consumption.
• Abdominal cramping and bloating.
• Diarrhea—may be watery or contain mucus.
• Fever greater than 38 °C (100.4 °F) in severe cases.
• Loss of appetite and general malaise.

Systemic (disseminated) infection

• Persistent high‑grade fever.
• Chills and night sweats.
• Unexplained weight loss.
• Muscle or joint pain.
• Shortness of breath if lungs are involved.
• Neurologic signs—headache, confusion, or focal deficits (rare).

Causes and Risk Factors

Primary cause

The infection originates from overgrowth of opportunistic yeasts in the kombucha brew. In a properly prepared batch, the SCOBY maintains a balanced micro‑ecosystem, keeping pathogenic organisms suppressed. However, when:

• Fermentation temperatures exceed 30 °C (86 °F),
• Brewing containers are not sterilized,
• Fermentation time is prolonged (> 30 days), or
• Contaminated water or ingredients are used,

the yeast component can dominate, producing high colony counts of Candida albicans, Candida tropicalis, or Saccharomyces cerevisiae. Ingestion or dermal exposure to this overgrown yeast can breach mucosal or skin barriers, leading to infection.

Risk factors

• Immunosuppression (HIV, chemotherapy, steroids, biologics).
• Diabetes mellitus—high glucose favors yeast growth.
• Existing skin lesions (eczema, psoriasis, wounds).
• Alcohol abuse—can impair immune defenses.
• Home‑brew practices that skip sterilization steps.

Diagnosis

Because the condition mimics more common bacterial cellulitis or viral gastroenteritis, a high index of suspicion is required.

Clinical assessment

• Detailed history of kombucha consumption/handling.
• Physical examination of skin lesions or abdominal findings.

Laboratory tests

• Complete blood count (CBC) – may show leukocytosis.
• Serum C‑reactive protein (CRP) / ESR – markers of inflammation.
• Blood cultures – essential if systemic signs are present; check for yeast growth.
• Swab or tissue biopsy of skin lesions – sent for fungal stain (PAS/KOH) and culture.
• Stool culture or PCR – in cases of gastrointestinal symptoms.
• Imaging (ultrasound, CT) – if deeper tissue involvement is suspected.

Diagnostic criteria (simplified)

1. Documented exposure to home‑brewed kombucha within the prior 2‑4 weeks.
2. Clinical signs consistent with fungal infection.
3. Isolation of yeast from the appropriate specimen (skin, blood, stool).
4. Exclusion of bacterial causes through culture and response to antibiotics.

Treatment Options

Therapy mirrors treatment of other opportunistic yeast infections but must be individualized based on infection site, severity, and patient comorbidities.

Antifungal medications

• Topical azoles (clotrimazole, miconazole) – for mild, localized skin infection.
• Oral fluconazole 100 mg daily for 7‑14 days – first‑line for uncomplicated cutaneous or gastrointestinal disease.
• Itraconazole 200 mg twice daily – useful for Candida species resistant to fluconazole.
• Echinocandins (caspofungin, micafungin) – reserved for severe systemic infection or when azoles are contraindicated.

Adjunctive measures

• Proper wound care: gentle cleansing, sterile dressings, and debridement if necrotic tissue is present.
• Hydration and electrolyte replacement for gastroenteritis.
• Probiotic supplementation (e.g., Lactobacillus spp.) after acute phase to restore gut flora.
• Review and adjust immunosuppressive therapy with the prescribing physician.

Procedural interventions

• Incision & drainage of an abscess if fluctuance develops.
• Endoscopic evaluation for persistent gastrointestinal symptoms not responding to medication.

Duration of therapy

Most cases resolve with 2‑3 weeks of antifungal therapy. Disseminated disease may require 6‑12 weeks and follow‑up cultures to confirm clearance.

Living with Kombucha Infection (Rare Fungal)

While the infection itself is treatable, patients often have lingering concerns about future exposures and overall health.

Practical daily tips

• Maintain skin integrity – keep any cuts or eczema moisturized and protected.
• Hand hygiene – wash hands with soap for at least 20 seconds after handling fermented foods.
• Monitor for recurrence – note any new rash, GI upset, or fever and seek prompt evaluation.
• Balanced diet – limit added sugars that can feed yeast overgrowth.
• Stay up‑to‑date with vaccinations (influenza, pneumococcal) to reduce overall infection risk.

Follow‑up care

Schedule a follow‑up visit 1‑2 weeks after completing antifungal therapy to ensure symptom resolution and review lab results. For immunocompromised patients, periodic fungal surveillance (e.g., serum β‑D‑glucan) may be recommended.

Prevention

Because the infection is linked to contaminated kombucha, prevention focuses on safe brewing practices and personal health measures.

Safe home‑brewing checklist

1. Sanitize all equipment (glass jars, lids, utensils) with a 1 % bleach solution or boiling water.
2. Use filtered or boiled water to eliminate environmental microbes.
3. Maintain proper temperature (20‑30 °C or 68‑86 °F) and avoid exposure to direct sunlight.
4. Limit fermentation time to 7‑14 days for typical home batches.
5. Inspect the SCOBY daily—any discoloration (black, pink) or foul odor indicates contamination.
6. Store the finished kombucha in the refrigerator and consume within 7 days.

General health measures

• Control blood glucose if diabetic.
• Avoid unnecessary antibiotics that can disrupt normal flora.
• Limit alcohol intake, which impairs immune function.
• Seek professional guidance before starting any fermentation hobby if you have a weakened immune system.

Complications

If left untreated or inadequately managed, kombucha‑related fungal infection can lead to serious outcomes:

• Cellulitis progression to necrotizing fasciitis (rare but life‑threatening).
• Systemic candidemia – bloodstream infection that can seed the heart, eyes, or brain.
• Chronic gastrointestinal dysbiosis – persistent diarrhea, malabsorption, and weight loss.
• Organ dysfunction – kidneys or liver injury from prolonged sepsis.
• In immunocompromised hosts, disseminated fungal infection carries a mortality rate of 30‑40 % (CDC, 2022).

When to Seek Emergency Care

---

**Sources:** Mayo Clinic. “Fungal skin infections.” 2023; CDC. “Invasive Candidiasis.” 2022; NIH National Institute of Allergy and Infectious Diseases. “Fungal disease overview.” 2024; WHO. “Mycoses – global burden.” 2023; Cleveland Clinic. “Home brewing safety.” 2023; Journal of Clinical Microbiology. “SCOBY‑associated infections: a case series.” 2021.